GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adaptive Biotechnologies Corp (FRA:1HM) » Definitions » EV-to-EBITDA

Adaptive Biotechnologies (FRA:1HM) EV-to-EBITDA : -1.49 (As of Jun. 25, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Adaptive Biotechnologies EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Adaptive Biotechnologies's enterprise value is €247.6 Mil. Adaptive Biotechnologies's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was €-166.1 Mil. Therefore, Adaptive Biotechnologies's EV-to-EBITDA for today is -1.49.

The historical rank and industry rank for Adaptive Biotechnologies's EV-to-EBITDA or its related term are showing as below:

FRA:1HM' s EV-to-EBITDA Range Over the Past 10 Years
Min: -107.34   Med: -7.58   Max: 0.39
Current: -1.47

During the past 7 years, the highest EV-to-EBITDA of Adaptive Biotechnologies was 0.39. The lowest was -107.34. And the median was -7.58.

FRA:1HM's EV-to-EBITDA is ranked worse than
100% of 459 companies
in the Biotechnology industry
Industry Median: 8.66 vs FRA:1HM: -1.47

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-25), Adaptive Biotechnologies's stock price is €3.003. Adaptive Biotechnologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €-1.377. Therefore, Adaptive Biotechnologies's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Adaptive Biotechnologies EV-to-EBITDA Historical Data

The historical data trend for Adaptive Biotechnologies's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adaptive Biotechnologies EV-to-EBITDA Chart

Adaptive Biotechnologies Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial -45.42 -52.37 -19.27 -4.01 -2.45

Adaptive Biotechnologies Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.65 -4.16 -3.25 -2.45 -1.45

Competitive Comparison of Adaptive Biotechnologies's EV-to-EBITDA

For the Biotechnology subindustry, Adaptive Biotechnologies's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adaptive Biotechnologies's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adaptive Biotechnologies's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Adaptive Biotechnologies's EV-to-EBITDA falls into.



Adaptive Biotechnologies EV-to-EBITDA Calculation

Adaptive Biotechnologies's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=247.618/-166.093
=-1.49

Adaptive Biotechnologies's current Enterprise Value is €247.6 Mil.
Adaptive Biotechnologies's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-166.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Adaptive Biotechnologies  (FRA:1HM) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Adaptive Biotechnologies's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=3.003/-1.377
=At Loss

Adaptive Biotechnologies's share price for today is €3.003.
Adaptive Biotechnologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.377.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Adaptive Biotechnologies EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Adaptive Biotechnologies's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Adaptive Biotechnologies (FRA:1HM) Business Description

Traded in Other Exchanges
Address
1165 Eastlake Avenue East, Seattle, WA, USA, 98109
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease ("MRD") in patients with multiple myeloma ("MM"), B cell acute lymphoblastic leukemia ("ALL") and chronic lymphocytic leukemia ("CLL") and is also available as a CLIA-validated laboratory developed test ("LDT") for patients with other lymphoid cancers, including diffuse large B-cell lymphoma ("DLBCL").

Adaptive Biotechnologies (FRA:1HM) Headlines

No Headlines